Cohort Study: Optimizing both disease control and glucocorticoid dosing is essential for bone protection in patients with rheumatic disease.
23 Jun, 2022 | 10:01h | UTCOptimising both disease control and glucocorticoid dosing is essential for bone protection in patients with rheumatic disease – Annals of Rheumatic Diseases (link to abstract – $ for full-text)
Commentary: Low-dose glucocorticoids show no negative impact on BMD – medwire News
Commentary on Twitter
New and important study on #glucocorticoids and bone health in inflammatory rheumatic diseases. https://t.co/6XakxJO37y doses <5 mg/d together with low disease activity seem to have a low risk for #osteoporosis pic.twitter.com/Na5eMHLMS3
— ARD & RMD Open (@ARD_BMJ) June 12, 2022